AAPL329.26+2.67 (+0.82%) ▲|ABBV255.55+2.17 (+0.86%) ▲|ABT100.86-0.81 (-0.79%) ▼|ACN141.15-3.59 (-2.48%) ▼|ADBE227.00-7.74 (-3.30%) ▼|AMAT565.50+39.80 (+7.57%) ▲|AMD535.45+31.88 (+6.33%) ▲|AMGN363.86-0.31 (-0.09%) ▼|AMT164.83-2.24 (-1.34%) ▼|AMZN247.42-2.57 (-1.03%) ▼|AVGO386.53+8.37 (+2.21%) ▲|AXP351.58-0.36 (-0.10%) ▼|BA210.55+1.07 (+0.51%) ▲|BAC61.37+0.95 (+1.56%) ▲|BKNG177.31-2.14 (-1.19%) ▼|BLK1,053.64-0.48 (-0.05%) ▼|BMY60.48+0.32 (+0.52%) ▲|BNY158.51+1.58 (+1.01%) ▲|BRK-B490.29-0.96 (-0.20%) ▼|C133.18+4.46 (+3.46%) ▲|CAT891.56+27.26 (+3.15%) ▲|CL90.20-1.74 (-1.89%) ▼|CMCSA23.69-0.10 (-0.40%) ▼|COF206.01-0.77 (-0.37%) ▼|COP116.99+1.31 (+1.13%) ▲|COST928.96-6.84 (-0.73%) ▼|CRM169.96-3.83 (-2.20%) ▼|CSCO111.18+0.48 (+0.43%) ▲|CVS109.45+1.84 (+1.71%) ▲|CVX190.07+0.36 (+0.19%) ▲|DE593.14+7.14 (+1.22%) ▲|DHR174.59-26.53 (-13.19%) ▼|DIS96.53+0.12 (+0.12%) ▲|DUK125.08-0.77 (-0.61%) ▼|EMR139.51+2.93 (+2.15%) ▲|FDX314.61+8.39 (+2.74%) ▲|GD370.74+0.14 (+0.04%) ▲|GE342.27+0.97 (+0.28%) ▲|GEV1,089.99+10.81 (+1.00%) ▲|GILD129.68-3.53 (-2.65%) ▼|GM78.91+3.11 (+4.10%) ▲|GOOG348.66-2.71 (-0.77%) ▼|GOOGL349.28-2.71 (-0.77%) ▼|GS1,080.93+25.90 (+2.45%) ▲|HD331.80-1.24 (-0.37%) ▼|HON231.64+5.46 (+2.41%) ▲|IBM211.01-1.99 (-0.93%) ▼|INTC104.36+7.30 (+7.52%) ▲|INTU289.56-4.26 (-1.45%) ▼|ISRG356.94+3.77 (+1.07%) ▲|JNJ250.61+1.79 (+0.72%) ▲|JPM344.94+6.07 (+1.79%) ▲|KO82.03-0.09 (-0.11%) ▼|LIN505.31-6.74 (-1.32%) ▼|LLY1,162.85+15.95 (+1.39%) ▲|LMT505.53-4.01 (-0.79%) ▼|LOW203.87-0.85 (-0.41%) ▼|LRCX322.12+15.36 (+5.01%) ▲|MA541.38-6.07 (-1.11%) ▼|MCD264.64-3.00 (-1.12%) ▼|MDLZ59.68-0.59 (-0.98%) ▼|MDT82.64-0.65 (-0.78%) ▼|META647.27+1.42 (+0.22%) ▲|MMM172.69+13.58 (+8.54%) ▲|MO73.48-1.18 (-1.58%) ▼|MRK125.55+1.15 (+0.92%) ▲|MS215.95+5.01 (+2.38%) ▲|MSFT397.87-4.43 (-1.10%) ▼|MU969.77+104.31 (+12.05%) ▲|NEE87.81-0.20 (-0.22%) ▼|NFLX66.85-0.75 (-1.11%) ▼|NKE43.26-0.22 (-0.49%) ▼|NOW102.24-2.46 (-2.35%) ▼|NVDA205.70+2.42 (+1.19%) ▲|ORCL125.49+4.11 (+3.38%) ▲|PEP134.61-0.86 (-0.63%) ▼|PFE24.89+0.14 (+0.55%) ▲|PG147.55-1.58 (-1.06%) ▼|PLTR133.37-1.48 (-1.10%) ▼|PM190.51-2.21 (-1.15%) ▼|QCOM174.23+3.91 (+2.30%) ▲|RTX196.40+1.96 (+1.01%) ▲|SBUX104.96+0.15 (+0.14%) ▲|SCHW102.57+0.03 (+0.03%) ▲|SO93.55-0.91 (-0.96%) ▼|SPG227.93-0.27 (-0.12%) ▼|T21.99+0.04 (+0.18%) ▲|TMO518.64-7.60 (-1.44%) ▼|TMUS191.19-4.45 (-2.27%) ▼|TSLA380.96+11.39 (+3.08%) ▲|TXN294.51+10.44 (+3.68%) ▲|UBER71.53-0.65 (-0.89%) ▼|UNH433.68+12.13 (+2.88%) ▲|UNP294.85-1.40 (-0.47%) ▼|UPS116.08+2.93 (+2.59%) ▲|USB63.45+0.31 (+0.48%) ▲|V358.32-2.25 (-0.62%) ▼|VZ43.37-0.14 (-0.31%) ▼|WFC87.89+1.56 (+1.80%) ▲|WMT110.29-1.91 (-1.70%) ▼|XOM150.97+2.61 (+1.76%) ▲|AAPL329.26+2.67 (+0.82%) ▲|ABBV255.55+2.17 (+0.86%) ▲|ABT100.86-0.81 (-0.79%) ▼|ACN141.15-3.59 (-2.48%) ▼|ADBE227.00-7.74 (-3.30%) ▼|AMAT565.50+39.80 (+7.57%) ▲|AMD535.45+31.88 (+6.33%) ▲|AMGN363.86-0.31 (-0.09%) ▼|AMT164.83-2.24 (-1.34%) ▼|AMZN247.42-2.57 (-1.03%) ▼|AVGO386.53+8.37 (+2.21%) ▲|AXP351.58-0.36 (-0.10%) ▼|BA210.55+1.07 (+0.51%) ▲|BAC61.37+0.95 (+1.56%) ▲|BKNG177.31-2.14 (-1.19%) ▼|BLK1,053.64-0.48 (-0.05%) ▼|BMY60.48+0.32 (+0.52%) ▲|BNY158.51+1.58 (+1.01%) ▲|BRK-B490.29-0.96 (-0.20%) ▼|C133.18+4.46 (+3.46%) ▲|CAT891.56+27.26 (+3.15%) ▲|CL90.20-1.74 (-1.89%) ▼|CMCSA23.69-0.10 (-0.40%) ▼|COF206.01-0.77 (-0.37%) ▼|COP116.99+1.31 (+1.13%) ▲|COST928.96-6.84 (-0.73%) ▼|CRM169.96-3.83 (-2.20%) ▼|CSCO111.18+0.48 (+0.43%) ▲|CVS109.45+1.84 (+1.71%) ▲|CVX190.07+0.36 (+0.19%) ▲|DE593.14+7.14 (+1.22%) ▲|DHR174.59-26.53 (-13.19%) ▼|DIS96.53+0.12 (+0.12%) ▲|DUK125.08-0.77 (-0.61%) ▼|EMR139.51+2.93 (+2.15%) ▲|FDX314.61+8.39 (+2.74%) ▲|GD370.74+0.14 (+0.04%) ▲|GE342.27+0.97 (+0.28%) ▲|GEV1,089.99+10.81 (+1.00%) ▲|GILD129.68-3.53 (-2.65%) ▼|GM78.91+3.11 (+4.10%) ▲|GOOG348.66-2.71 (-0.77%) ▼|GOOGL349.28-2.71 (-0.77%) ▼|GS1,080.93+25.90 (+2.45%) ▲|HD331.80-1.24 (-0.37%) ▼|HON231.64+5.46 (+2.41%) ▲|IBM211.01-1.99 (-0.93%) ▼|INTC104.36+7.30 (+7.52%) ▲|INTU289.56-4.26 (-1.45%) ▼|ISRG356.94+3.77 (+1.07%) ▲|JNJ250.61+1.79 (+0.72%) ▲|JPM344.94+6.07 (+1.79%) ▲|KO82.03-0.09 (-0.11%) ▼|LIN505.31-6.74 (-1.32%) ▼|LLY1,162.85+15.95 (+1.39%) ▲|LMT505.53-4.01 (-0.79%) ▼|LOW203.87-0.85 (-0.41%) ▼|LRCX322.12+15.36 (+5.01%) ▲|MA541.38-6.07 (-1.11%) ▼|MCD264.64-3.00 (-1.12%) ▼|MDLZ59.68-0.59 (-0.98%) ▼|MDT82.64-0.65 (-0.78%) ▼|META647.27+1.42 (+0.22%) ▲|MMM172.69+13.58 (+8.54%) ▲|MO73.48-1.18 (-1.58%) ▼|MRK125.55+1.15 (+0.92%) ▲|MS215.95+5.01 (+2.38%) ▲|MSFT397.87-4.43 (-1.10%) ▼|MU969.77+104.31 (+12.05%) ▲|NEE87.81-0.20 (-0.22%) ▼|NFLX66.85-0.75 (-1.11%) ▼|NKE43.26-0.22 (-0.49%) ▼|NOW102.24-2.46 (-2.35%) ▼|NVDA205.70+2.42 (+1.19%) ▲|ORCL125.49+4.11 (+3.38%) ▲|PEP134.61-0.86 (-0.63%) ▼|PFE24.89+0.14 (+0.55%) ▲|PG147.55-1.58 (-1.06%) ▼|PLTR133.37-1.48 (-1.10%) ▼|PM190.51-2.21 (-1.15%) ▼|QCOM174.23+3.91 (+2.30%) ▲|RTX196.40+1.96 (+1.01%) ▲|SBUX104.96+0.15 (+0.14%) ▲|SCHW102.57+0.03 (+0.03%) ▲|SO93.55-0.91 (-0.96%) ▼|SPG227.93-0.27 (-0.12%) ▼|T21.99+0.04 (+0.18%) ▲|TMO518.64-7.60 (-1.44%) ▼|TMUS191.19-4.45 (-2.27%) ▼|TSLA380.96+11.39 (+3.08%) ▲|TXN294.51+10.44 (+3.68%) ▲|UBER71.53-0.65 (-0.89%) ▼|UNH433.68+12.13 (+2.88%) ▲|UNP294.85-1.40 (-0.47%) ▼|UPS116.08+2.93 (+2.59%) ▲|USB63.45+0.31 (+0.48%) ▲|V358.32-2.25 (-0.62%) ▼|VZ43.37-0.14 (-0.31%) ▼|WFC87.89+1.56 (+1.80%) ▲|WMT110.29-1.91 (-1.70%) ▼|XOM150.97+2.61 (+1.76%) ▲|
24.8 C
New York
Tuesday, July 21, 2026

Tag: intravenous infusions

newssourceFORcompanyinformationcontent1releasesmarket

Capricor to Present Positive Five-Year HOPE-2 OLE Data and HOPE-3 Phase 3 Results for Deramiocel in Duchenne Muscular Dystrophy at PPMD 2026 Annual Conference

SAN DIEGO, June 26, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases, today announced positive five-year data from its ongoing HOPE-2 Open-Label Extension (OLE) study of Deramiocel, the Company’s lead cell therapy candidate for Duchenne Muscular Dystrophy (DMD). The data will be presented at the Parent Project Muscular Dystrophy (PPMD) 2026 Annual Conference, taking place June 25-27, 2026, in Orlando, Florida, alongside previously reported results from the Company’s HOPE-3 Phase 3 trial.

Novartis ianalumab Phase III trial meets primary endpoint in ITP, demonstrating statistically significant improvement in time to treatment failure

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsIntravenous infusions

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers